Hyo Jeong Hong

This inventor holds 13 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Korea Research Institute of Bioscience and Biotechnology, Aprogen Inc., Geneone Life Science, Inc.. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hyo Jeong Hong. Retrieved from https://idiyas.com/inventor/hyo-jeong-hong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 2)

% Patents Active = 69.2

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 58(Granted Patents)

Location History:

Taejon, KR (2002 - 2012)
Daejeon, KR (2012 - 2013)
Gongju-si, KR (2014)
Chuncheon-si, KR (2016 - 2017)
Seoul, KR (2017 - 2021)

Company Filing History:

4 out of 334

Korea Research Institute of Bioscience and Biotechnology

Geneone Life Science, Inc.

patents

4. 2 out of 24

Kangwon National University University-Industry Cooperation Foundation

Industry-University Cooperation Foundation Hanyang University

patents

7. 1 out of 2,792

Korea Advanced Institute of Science and Technology

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12509513 - ANTI-L1CAM ANTIBODIES AND USES THEREOF (2025-12-30),

2. 10961300 - Antibody specifically binding to an isolated peptide derived from vimentin or a fragment binding to the peptide (2021-03-30),

3. 10196437 - Antibody binding specifically to pre-S1 of hepatitis B virus and use of the antibody (2019-02-05),

4. 9777060 - Antibody binding specifically to human and mouse L1CAM protein, and use therefor (2017-10-03),

5. 9683042 - T-cell-specific humanized single fragment antibody delivery vehicle (2017-06-20),

6. 9605043 - Fusion protein for suppressing cancer cell growth and suppressing vasculogenesis, and anticancer composition comprising same (2017-03-28),

7. 9512235 - RNA-specific binding antibody (2016-12-06),

8. 8778901 - Anticancer drug comprising inhibitor of TMPRSS4 (2014-07-15),

9. 8420353 - Humanized antibody and process for preparing same (2013-04-16),

10. 8268316 - Monoclonal antibody specific to anthrax toxin (2012-09-18),

11. 8153122 - Pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma (2012-04-10),

12. 8119132 - Humanized anti-tag-72 monoclonal antibodies (2012-02-21),

13. 6458934 - Humanized antibody specific for human 4-1BB (2002-10-01),

Title: The Innovative Mind of Hyo Jeong Hong

Introduction: Hyo Jeong Hong is a pioneering inventor hailing from Daejeon, South Korea, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Hyo Jeong Hong holds several patents in the realm of electronics and telecommunications, showcasing his continuous dedication to pushing the boundaries of what is possible in the industry.

Career Highlights: With a career spanning over two decades, Hyo Jeong Hong has worked tirelessly to develop cutting-edge solutions that have revolutionized the way we interact with technology. His keen eye for detail and passion for innovation have led to the creation of numerous products that have had a lasting impact on the market.

Collaborations: Throughout his career, Hyo Jeong Hong has collaborated with leading tech companies and research institutions, pooling together expertise to drive forward progress in the field. His ability to work effectively in teams has been instrumental in the success of many projects.

Conclusion: In conclusion, Hyo Jeong Hong stands as a beacon of innovation in the world of technology, with a legacy that continues to inspire budding inventors and entrepreneurs alike. His relentless pursuit of excellence and unwavering commitment to innovation make him a true trailblazer in his field.

Profile summary based on public USPTO records.